文献速递贫血与红细胞疾病血栓与止血

伊普可泮治疗免疫性血小板减少症与冷凝集素病:一项全球2期篮式临床试验

Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial.
PubMed 文献 · Am J Hematol · 2025-12-09

这项全球多中心2期篮式研究评估伊普可泮单药治疗经至少1种既往治疗失败的原发性ITP或CAD成人患者,共19例(ITP 9例,CAD 10例)。CAD患者中5例(50%)达到主要终点,血红蛋白自基线至第12周平均升高2.2 g/dL;ITP患者无一达到主要终点。伊普可泮在CAD中显示初步疗效,在两种疾病中耐受性良好,无意外安全信号。

要点

  • CAD患者中5例(50%)达到血红蛋白主要终点,自基线至第12周平均升高2.2 g/dL。
  • ITP患者无一达到方案定义的血小板主要终点。
  • 多数治疗中出现的不良事件为轻度,最常见为头痛(21%)、乏力(16%)、疲乏(16%)和瘀点(16%)。

核心结论

  • 伊普可泮单药在原发性CAD中显示令人鼓舞的初步疗效,而在原发性ITP中未观察到方案定义的缓解。
  • 伊普可泮可能成为CAD有前景的口服选择,且在ITP和CAD中耐受性良好,无意外安全信号。

研究设计与样本

  • 全球、多中心、2期篮式研究,纳入至少1种既往治疗失败的原发性ITP或CAD成人患者。
  • 共19例患者接受伊普可泮治疗,其中ITP 9例、CAD 10例。
  • 主要终点:ITP为血小板反应(≥50×10^9/L),CAD为血红蛋白反应(升高≥1.5 g/dL),均需在伊普可泮治疗前12周内连续≥2周持续且未使用补救治疗。
  • 其他终点包括至首次反应时间、反应持续时间、药代动力学、安全性/耐受性和FACIT-疲乏量表。
  • 试验注册号:ClinicalTrials.gov NCT05086744。

主要发现

  • CAD患者中多数血红蛋白水平改善,自基线至第12周平均升高2.2 g/dL;5例(50%)达到主要终点。
  • CAD其他结局亦改善,包括乳酸脱氢酶、胆红素、网织红细胞和FACIT-疲乏量表。
  • ITP患者无一达到主要终点。
  • 多数治疗中出现的不良事件为轻度,最常见为头痛(21%)、乏力(16%)、疲乏(16%)和瘀点(16%)。

关键数值与推荐

  • ITP主要终点为血小板≥50×10^9/L并持续≥2周;CAD主要终点为血红蛋白升高≥1.5 g/dL并持续≥2周。
  • CAD中5例(50%)达到主要终点;ITP中0例达到主要终点。
  • CAD自基线至第12周血红蛋白平均升高2.2 g/dL。
  • 最常见治疗中出现的不良事件:头痛21%、乏力16%、疲乏16%、瘀点16%。

临床怎么用

  • 作者认为伊普可泮单药在原发性CAD中显示令人鼓舞的初步疗效,可能成为CAD有前景的口服选择。
  • 作者报告伊普可泮在ITP和CAD中耐受性良好,无意外安全信号。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iptacopan is a first-in-class, oral, selective inhibitor of complement factor B that has demonstrated positive efficacy across several complement-driven diseases. Here we evaluate the efficacy and safety of iptacopan monotherapy in adult patients with primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). We performed a global, multicenter, phase 2 basket study enrolling patients with primary ITP or CAD after failure of ≥ 1 unique prior therapies. Primary endpoints were platelet response (≥ 50 × 109/L) for ITP and hemoglobin response (≥ 1.5 g/dL increase) for CAD sustained for ≥ 2 consecutive weeks during the first 12 weeks of iptacopan treatment, without the use of rescue therapy. Other endpoints included time to first response, duration of response, pharmacokinetics, safety/tolerability, and FACIT-Fatigue. Nineteen patients were treated with iptacopan (9 ITP, 10 CAD). Among patients with CAD, most showed improvements in hemoglobin levels, with a mean increase of 2.2 g/dL from baseline to week 12; five (50%) patients achieved the primary endpoint. Improvements were also observed for other outcomes in CAD, including lactate dehydrogenase, bilirubin, reticulocytes, and FACIT-Fatigue. Conversely, no patients with ITP met the primary endpoint. Most treatment-emergent adverse events (TEAEs) were mild, the most common being headache (21%), asthenia (16%), fatigue (16%), and petechiae (16%). Iptacopan monotherapy demonstrated encouraging preliminary efficacy in primary CAD, while no protocol-defined responses were observed in primary ITP. Iptacopan may represent a promising oral option for CAD and was well tolerated in both ITP and CAD with no unexpected safety signals. Trial Registration: ClinicalTrials.gov identifier: NCT05086744.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Röth A, Barcellini W, Ademokun C, et al. Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial. Am J Hematol. 2025. PMID: 41366634. doi:10.1002/ajh.70147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。